Neurocognitive outcomes are not improved by 17β-estradiol in postmenopausal women undergoing cardiac surgery

Stroke

Volumn 38, Issue 7, 2007, Pages 2048-2054

  Hogue Jr , Charles W ^a,c   Freedland, Kenneth ^b   Hershey, Tamara ^b   Fucetola, Robert ^b   Nassief, Abullah ^b   Barzilai, Benico ^b   Thomas, Betsy ^b   Birge, Stanley ^b   Dixon, David ^b   Schechtman, Kenneth B ^b   Dávila Román, Victor G ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Cardiac surgery; Cognitive impairment; Estrogen; Neuroprotective agents

Indexed keywords

ESTRADIOL; PLACEBO;

AGED; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; COGNITIVE DEFECT; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; ESTROGEN THERAPY; FEMALE; HEART SURGERY; HEART VALVE SURGERY; HUMAN; MAJOR CLINICAL STUDY; NEUROPROTECTION; PERIOPERATIVE PERIOD; POSTMENOPAUSE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOMETRY; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT DURATION; TREATMENT OUTCOME;

BRAIN ISCHEMIA; CARDIAC SURGICAL PROCEDURES; COGNITION; COGNITION DISORDERS; ESTRADIOL; FEMALE; HUMANS; INTRAOPERATIVE COMPLICATIONS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 34347331306     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.106.480426     Document Type: Article

References (48)

1. Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM, Goldstein LB, Gorelick PB, Howard G, Kittner SJ, Manolio TA, Whisnant JP, Wolf PA. American Heart Association Prevention Conference IV: prevention and rehabilitation of stroke: risk factors. Stroke. 1997;28:1507-1517.
2. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med. 1993;329:247-256.
3. Wyller TB, Sodring KM, Sveen U, Ljunggren AE, Bautz-Holter E. Are there gender differences in functional outcome after stroke? Clin Rehabil. 1997;11:171-179.
4. Hurn PD, Macrae IM. Estrogen as a neuroprotectant in stroke. J Cereb Blood Flow Metab. 2000;20:631-652.
5. Hogue CW Jr, Murphy SF, Schechtman KB, Dávila-Román VG. Risk factors for early or delayed stroke after cardiac surgery. Circulation. 1999;100:642-647.
6. Hogue CW Jr, Barzilai B, Pieper KS, Coombs LP, DeLong ER, Kouchoukos NT, Davila-Roman VG. Sex differences in neurologic outcomes and mortality after cardiac surgery: a Society of Thoracic Surgery National Database Report. Circulation. 2001;103:2133-2137.
7. Simpkins JW, Rajakumar G, Zhang YQ, Simpkins CE, Greenwald D, Yu CJ, Bodor N, Day AL. Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. J Neurosurg. 1997;87:724-730.
8. Alkayed NJ, Harukuni I, Kimes AS, London ED, Traystman RJ, Hurn PD. Gender-linked brain injury in experimental stroke. Stroke. 1998;29:159-166.
9. Dubal DB, Kashon ML, Pettigrew LC, Ren JM, Finklestein SP, Rau SW, Wise PM. Estradiol protects against ischemic injury. J Cereb Blood Flow Metab. 1998;18:1253-1258.
10. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
11. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, Barrett-Connor E, Hulley SB, for the HERS Research Group. Postmenopausal hormone therapy and risk of stroke. Circulation. 2001;103:638-642.
12. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243-1249.
13. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
14. Wassertheil-Smoller S, Hendrix SL, Limacher M, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ, and the Women's Health Initiative Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA. 2003;289:2673-2684.
15. The Women's Health Initiative Steering Committee. Effect of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. 2004;291:1701-1712.
16. Kuhnz W, Gansau C, Mahler M. Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17β-estradiol. Drug Res. 1993;43:966-973.
17. White CM, Ferraro-Borgida MJ, Fossati AT, McGill CC, Ahlberg AW, Feng YJ, Heller GV, Chow MS. The pharmacokinetics of intravenous estradiol: a preliminary study. Pharmacotherapy. 1998;18:1343-1346.
18. Abraham GE, Odell WD, Swerdloff RS, Hopper K. Simultaneous radio-immunoassay plasma FSH, GH, progesterone, 17-hydroxy-progesterone and estradiol-17β during the menstrual cycle. J Clin Endrocrinol Metab. 1972;34:312-316.
19. Powell JB, Cripe LI, Dodrill CB. Assessment of brain impairment with the Rey Auditory-Verbal Learning Test. Arch Clin Neuropsychol. 1991;6:241-249.
20. Spreen O, Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, 2nd ed. New York: Oxford University Press; 1998.
21. Wechsler D. Wechsler Memory Scale-Revised. San Antonio, Tex: Psychological Corp; 1997.
22. Wechsler D. Wechsler Adult Intelligence Scale-III. New York: Psychological Corp; 1991.
23. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery. Tucson, Ariz: Neuropsychology Press; 1985.
24. Costa LD, Vaughan HG, Levita E, Farber N. Purdue Pegboard as a predictor of the presence and laterality of cerebral lesions. J Consult Psychol. 1963;56:295-297.
25. Dee HL, Benton AL. A cross-modal investigation of spatial performance in patients with unilateral cerebral disease. Cortex. 1970;6:261-272.
26. Stump DA. Selection and clinical significance of neuropsychological tests. Ann Thorac Surg. 1995;59:1340-1344.
27. Beck AT, Ward CH, Mendelsohn M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
28. Beck AT, Steer RA. Beck Anxiety Inventory (BAI) Manual. San Antonio, Tex: Psychological Corp; 1993.
29. Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH Stroke Scale. Arch Neurol. 1989;46:660-662.
30. Hogue CW Jr, Hershey T, Dixon D, Fucetola R, Nassief A, Freedland KE, Thomas B, Schechtman K. Preexisting cognitive impairment in women before cardiac surgery and its relationship with C-reactive protein. Anesth Analg. 2006;102:1602-1608.
31. Lasocki S, Provenchére S, Bénessiano J, Vicaut E, Lecharny JB, Desmonts JM, Dehoux M, Philip I. Cardiac troponin I is an independent predictor of in-hospital death after adult cardiac surgery. Anesthesiology. 2002;97:405-411.
32. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
33. Lewis M, Maruff P, Silbert B, Evered L, Scott D. The sensitivity and specificity of three common statistical rules for the classification of postoperative cognitive dysfunction following coronary artery bypass graft surgery. Acta Anaesthesiol Scan. 2006;50:50-57.
34. Hogue CW Jr, Palin CA, Arrowsmith JE. Cardiopulmonary bypass management and neurologic outcomes: an evidence-based appraisal of current practices. Anesth Analg. 2006;103:21-37.
35. Roach GW, Kanchuger M, Mora-Mangano C, Newman M, Nussmeier N, Wolman R, Aggarwal A, Marschall K, Graham SH, Ley C. Adverse cerebral outcomes after coronary bypass surgery. N Engl J Med. 1996;335:1857-1863.
36. Newman MF, Grocott HP, Mathew JP. White WD, Landolfo K, Reves JG, Laskowitz DT, Mark DB, Blumenthal JA; Neurologic Outcome Research Group and the Cardiothoracic Anesthesia Research Endeavors (CARE) Investigators of the Duke Heart Center. Report of the substudy assessing impact of neurocognitive function on quality of life 5 years after cardiac surgery. Stroke. 2001;32:2874-2881.
37. Newman MF, Kirchner JL, Phillips-Bute B, Gaver V, Grocott H, Jones RH, Mark DB, Reves JG, Blumenthal JA; Neurological Outcome Research Group and the Cardiothoracic Anesthesiology Research Endeavors Investigators. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med. 2001;344:395-402.
38. Selnes OA, Grega MA, Borowicz LM, Barry S, Zeger S, Baumgartner WA, McKhann GM. Cognitive outcomes three years after coronary artery bypass: a comparison of on-pump coronary artery bypass graft surgery and non-surgical controls. Ann Thorac Surg. 2005;79:1201-1209.
39. Klaiber EL, Vogel W, Rako S. A critique of the Women's Health Initiative hormone therapy study. Fertil Steril. 2005;84:1589-1601.
40. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health. 2006;15:35-44.
41. del Zoppo GJ. Stroke and neurovascular protection. N Engl J Med. 2006;354:553-555.
42. Goto T, Baba T, Honma K, Shibata Y, Arai Y, Uozumi H, Okuda T. Magnetic resonance imaging findings and postoperative neurologic dysfunction in elderly patients undergoing coronary artery bypass grafting. Ann Thorac Surg. 2001;72:137-142.
43. Moraca R, Lin E, Holmes JH IV, Fordyce D, Campbell W, Ditkoff M, Hill M, Guyton S, Paull D, Hall RA. Impaired baseline regional cerebral perfusion in patients referred for coronary artery bypass. J Thorac Cardiovasc Surg. 2006;131:540-546.
44. Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, McGovern P, Folsom AR; Atherosclerosis Risk in Communities (ARIC) Study Investigators. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology. 2001;56:42-48.
45. Henderson VW, Paganini-Hill A, Miller BL, Elble RJ, Reyes PF, Shoupe D, McCleary CA, Klein RA, Hake AM, Farlow MR. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebocontrolled trial. Neurology. 2000;54:295-301.
46. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease. JAMA. 2000;283:1007-1015.
47. Wang PN, Liao SQ, Liu RS, Liu CY, Chao HT, Lu SR, Yu HY, Wang SJ, Liu HC. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology. 2000;54:2061-2066.
48. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane D, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH, for the Women's Health Initiative Memory Study Investigations. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291:2947-2958.